Foster & Motley Inc. Decreases Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• Foster & Motley Inc. reduced its stake in Eli Lilly and Company by 42.8%, holding 890 shares worth approximately $735,000 at the end of the 1st quarter.
• Eli Lilly's stock rose 2.9% on a recent trading day, reaching $761.47, with a market capitalization of $721.68 billion.
• The company announced a quarterly dividend of $1.50 per share, yielding 0.8%, to be paid on September 10th.

Foster & Motley Inc. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 42.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 890 shares of the company's stock after selling 666 shares during the period. Foster & Motley Inc.'s holdings in Eli Lilly and Company were worth $735,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of LLY. GAMMA Investing LLC boosted its holdings in shares of Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares during the last quarter. Capital International Investors raised its position in Eli Lilly and Company by 23.2% in the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after purchasing an additional 1,645,222 shares during the period. Capital Research Global Investors raised its position in Eli Lilly and Company by 16.1% in the fourth quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock valued at $8,304,811,000 after purchasing an additional 1,493,673 shares during the period. Northern Trust Corp raised its position in Eli Lilly and Company by 14.6% in the fourth quarter. Northern Trust Corp now owns 9,448,219 shares of the company's stock valued at $7,294,025,000 after purchasing an additional 1,204,337 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Eli Lilly and Company by 15.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company's stock valued at $5,469,527,000 after acquiring an additional 969,376 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 2.9%

LLY traded up $21.40 during trading on Friday, hitting $761.47. The company's stock had a trading volume of 4,857,388 shares, compared to its average volume of 3,285,034. The firm's 50 day moving average price is $775.51 and its 200-day moving average price is $799.86. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The stock has a market cap of $721.67 billion, a PE ratio of 61.96, a PEG ratio of 1.05 and a beta of 0.44. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the prior year, the firm earned $2.58 earnings per share. The firm's quarterly revenue was up 45.2% on a year-over-year basis. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is currently 48.82%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent research reports. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research note on Friday, July 11th. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.